In January 2025, 66-year-old Tim Andrews underwent a pioneering medical procedure to receive a genetically modified pig kidney. The transplant was performed as a treatment for his end-stage kidney disease. According to reports, the patient survived for nine months following the surgery, marking a notable duration for a xenotransplant—the process of grafting or transplanting organs or tissues between members of different species.

While the procedure is being hailed as a significant step forward in medical science, it highlights the ongoing challenges in addressing the global shortage of human organs available for transplant. The genetic modification of the pig kidney was intended to reduce the risk of organ rejection by the human immune system. The success of this case provides researchers with critical data regarding how human bodies interact with non-human organs over an extended period. Further clinical trials and ethical reviews are expected to follow as the medical community evaluates the long-term viability and safety of such procedures for broader patient populations.